TY - JOUR
T1 - Access to effective antimicrobials
T2 - A worldwide challenge
AU - Laxminarayan, Ramanan
AU - Matsoso, Precious
AU - Pant, Suraj
AU - Brower, Charles
AU - Røttingen, John Arne
AU - Klugman, Keith
AU - Davies, Sally
N1 - Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/1/9
Y1 - 2016/1/9
N2 - Recent years have seen substantial improvements in life expectancy and access to antimicrobials, especially in low-income and lower-middle-income countries, but increasing pathogen resistance to antimicrobials threatens to roll back this progress. Resistant organisms in health-care and community settings pose a threat to survival rates from serious infections, including neonatal sepsis and health-care-associated infections, and limit the potential health benefits from surgeries, transplants, and cancer treatment. The challenge of simultaneously expanding appropriate access to antimicrobials, while restricting inappropriate access, particularly to expensive, newer generation antimicrobials, is unique in global health and requires new approaches to financing and delivering health care and a one-health perspective on the connections between pathogen transmission in animals and humans. Here, we describe the importance of effective antimicrobials. We assess the disease burden caused by limited access to antimicrobials, attributable to resistance to antimicrobials, and the potential effect of vaccines in restricting the need for antibiotics.
AB - Recent years have seen substantial improvements in life expectancy and access to antimicrobials, especially in low-income and lower-middle-income countries, but increasing pathogen resistance to antimicrobials threatens to roll back this progress. Resistant organisms in health-care and community settings pose a threat to survival rates from serious infections, including neonatal sepsis and health-care-associated infections, and limit the potential health benefits from surgeries, transplants, and cancer treatment. The challenge of simultaneously expanding appropriate access to antimicrobials, while restricting inappropriate access, particularly to expensive, newer generation antimicrobials, is unique in global health and requires new approaches to financing and delivering health care and a one-health perspective on the connections between pathogen transmission in animals and humans. Here, we describe the importance of effective antimicrobials. We assess the disease burden caused by limited access to antimicrobials, attributable to resistance to antimicrobials, and the potential effect of vaccines in restricting the need for antibiotics.
UR - http://www.scopus.com/inward/record.url?scp=84954077248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954077248&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(15)00474-2
DO - 10.1016/S0140-6736(15)00474-2
M3 - Review article
C2 - 26603918
AN - SCOPUS:84954077248
SN - 0140-6736
VL - 387
SP - 168
EP - 175
JO - The Lancet
JF - The Lancet
IS - 10014
ER -